IKT Inhibikase Therapeutics, Inc.
Price Chart
Executive Summary
Inhibikase Therapeutics announced the enrollment of the first patient in its global Phase 3 IMPROVE-PAH trial for IKT-001, a treatment candidate for pulmonary arterial hypertension. This marks a key milestone in the drug's development pathway toward potential NDA submission.
Actionable Insight
Monitor for future enrollment updates and interim data readouts from the IMPROVE-PAH trial, which could serve as catalysts for the stock. The progression to Phase 3 represents derisking of the clinical program, but no commercial or financial implications are immediate.
Key Facts
- Inhibikase Therapeutics (IKT) enrolled the first patient in its Phase 3 IMPROVE-PAH study for IKT-001 in pulmonary arterial hypertension (PAH)
- The trial is a two-part adaptive study with approximately 140 patients in Part A and 346 in Part B
- Primary endpoints are change in Pulmonary Vascular Resistance (PVR) at Week 24 for Part A and change in 6-minute walk distance (6MWD) at Week 24 for Part B
- The study will be conducted at up to approximately 180 sites globally
- IKT-001 is a novel oral prodrug of imatinib mesylate designed to reduce gastrointestinal side effects
Financial Impact
No immediate financial impact disclosed; this is a clinical development milestone
Risk Factors
- Clinical trial may encounter safety or efficacy issues leading to discontinuation
- Enrollment may be slower than anticipated
- IKT-001 may not demonstrate sufficient benefit over existing PAH therapies
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-144582 |
| Document: d108350dex991.htm | 0001193125-26-144582 |
| Document: 0001193125-26-144582-index-headers.html | 0001193125-26-144582 |
| Document: 0001193125-26-144582-index.html | 0001193125-26-144582 |
| Document: 0001193125-26-144582.txt | 0001193125-26-144582 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 12, 2026
28d ago
|
8-K
| $1.90 $1.57 | ▼ −17.37% | ▼ −16.21% | $1.62 (−14.74%) |
|
May 12, 2026
28d ago
|
Press Release
| $1.90 $1.57 | ▼ −17.37% | ▼ −16.21% | $1.62 (−14.74%) |
|
Apr 7, 2026
9w ago
|
8-K
| $1.76 $1.70 | ▼ −3.41% | ▼ −8.74% | $1.62 (−7.95%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access